Payment overview · 2025
General Payments
$1,169.48
86 reported records · 14 companies
Healthcare provider profile · identity verified
Mark E Albey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BENTON, AR · NPI 1043340011
Verified facts
What the public records show
CMS Open Payments records show Mark E Albey, M.D. received $1,169.48 in general payments during 2025 across 86 reported records.
PFIZER INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $257.34 | 22.0% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.36 | 16.1% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.88 | 13.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.56 | 12.7% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.12 | 11.6% | 18 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $74.08 | 6.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.03 | 6.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.10 | 3.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.77 | 2.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.80 | 1.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.46 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.21 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.72 | 1.2% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $6.05 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,169.48 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.72 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $143.39 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $143.10 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $135.12 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.89 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $88.62 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $88.62 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $88.62 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $74.08 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.03 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.27 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $67.09 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.88 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.88 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.77 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.59 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.33 | 2 | 2025 |
Source payment records
|
|||||
| SWIFT-LOCK Normalized: swift lock |
Device | Abbott Laboratories | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.49 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $10.23 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $6.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 253 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
253 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 881 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 838 | 182 |
| Pantoprazole Sodium | Pantoprazole Sodium | 811 | 158 |
| Metformin Hcl | Metformin Hcl | 527 | 103 |
| Gabapentin | Gabapentin | 519 | 114 |
| Omeprazole | Omeprazole | 514 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 512 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 468 | 87 |
| Lisinopril | Lisinopril | 453 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 423 | 82 |
| Meloxicam | Meloxicam | 390 | 102 |
| Glimepiride | Glimepiride | 386 | 69 |
| Tramadol Hcl | Tramadol Hcl | 350 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 335 | 92 |
| Potassium Chloride | Potassium Chloride | 331 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 329 | 88 |
| Losartan Potassium | Losartan Potassium | 327 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 50 |
| Metformin Hcl Er | Metformin Hcl | 281 | 62 |
| Simvastatin | Simvastatin | 271 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 256 | 62 |
| Jardiance | Empagliflozin | 253 | 35 |
| Furosemide | Furosemide | 242 | 44 |
| Alprazolam | Alprazolam | 239 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 233 | 43 |
| Trazodone Hcl | Trazodone Hcl | 231 | 52 |
| Allopurinol | Allopurinol | 219 | 46 |
| Carvedilol | Carvedilol | 209 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 202 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 202 | 60 |
| Eliquis | Apixaban | 180 | 24 |
| Ozempic | Semaglutide | 163 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 24 |
| Sertraline Hcl | Sertraline Hcl | 149 | 22 |
| Spironolactone | Spironolactone | 147 | 30 |
| Cefdinir | Cefdinir | 146 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 134 | 24 |
| Clonazepam | Clonazepam | 130 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 122 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 117 | 19 |
| Montelukast Sodium | Montelukast Sodium | 112 | 17 |
| Alendronate Sodium | Alendronate Sodium | 107 | 15 |
| Atenolol | Atenolol | 107 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 19 |
| Farxiga | Dapagliflozin Propanediol | 99 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 17 |
| Warfarin Sodium | Warfarin Sodium | 97 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 35 |
| Donepezil Hcl | Donepezil Hcl | 87 | 17 |
| Ezetimibe | Ezetimibe | 87 | 17 |
| Glipizide | Glipizide | 87 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 40 |
| Baclofen | Baclofen | 84 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 15 |
| Divalproex Sodium | Divalproex Sodium | 81 | 12 |
| Mounjaro | Tirzepatide | 79 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 19 |
| Clonidine Hcl | Clonidine Hcl | 75 | 13 |
| Mirtazapine | Mirtazapine | 73 | 16 |
| Bupropion Xl | Bupropion Hcl | 68 | 17 |
| Estradiol | Estradiol | 66 | 13 |
| Lansoprazole | Lansoprazole | 66 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 14 |
| Fluconazole | Fluconazole | 60 | 32 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Sucralfate | Sucralfate | 60 | suppressed |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 42 |
| Risperidone | Risperidone | 58 | suppressed |
| Temazepam | Temazepam | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 55 | suppressed |
| Prednisone | Prednisone | 55 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 12 |
| Primidone | Primidone | 53 | 13 |
| Pregabalin | Pregabalin | 52 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | suppressed |
| Levofloxacin | Levofloxacin | 50 | 40 |
| Lorazepam | Lorazepam | 50 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Olanzapine | Olanzapine | 45 | suppressed |
| Fenofibrate | Fenofibrate | 44 | suppressed |
| Indapamide | Indapamide | 44 | 16 |
| Irbesartan | Irbesartan | 44 | 11 |
| Naproxen | Naproxen | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Famotidine | Famotidine | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 33 |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Finasteride | Finasteride | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 13 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 19 |
| Nystatin | Nystatin | 27 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 27 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Niacin Er | Niacin | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 16 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Acetic Acid | Acetic Acid | 23 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Promethazine Hcl | Promethazine Hcl | 22 | 12 |
| Metronidazole | Metronidazole | 20 | 13 |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Clozapine | Clozapine | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 12 | suppressed |
| Fluoxetine Dr | Fluoxetine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,169.48 · 86 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, CARDIOMEMS, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SWIFT-LOCK, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XYOSTED, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error